2M.D. Associate Professor, Şişli Etfal Training and Research Hospital, 1st Eye Clinic, İstanbul/TURKEY
3M.D. Şişli Etfal Training and Research Hospital, 1st Eye Clinic, Purpose: To evaluate the efficacy of timolol, timolol-dorzolamide and timolol-brimonidine drops used prophylactically before IVB on the prevention of IOP rise.
Materials and Methods: Sixty four non-glaucomatous patients received 2.5 mg IVB for choroidal neovascularisation (NV) not secondary to senile macular degeneration, macular edema or retinal NV IOP measurement at arrival, 1 hour after instillation of artificial eye drop (Group A-placebo group), timolol (Group B), timolol-dorzolamide (Group C) or timolol-brimonidine drops (Group D), 30 minutes and 90 minutes after IVB.
Results: Mean IOP values were 16.2/15.5/17.8/16.2 mmHg for Group A (n=10), 16.2/13.8/16.6/14.7 for Group B (n=16), 16.1/13.5/17.5/15.3 for Group C (n=23) and 14.9/13.8/13.7/13.1 for Group D (n=15) respectively. Median IOP values were 15.50/16.50/19.00/16.00 mmHg for Group A (n=10), 16.00/14.50/16.50/15.00 for Group B (n=16), 16.00/13.00/17.00/15.00 for Group C (n=23) and 14.00/13.00/13.00/11.00 for Group D (n=15). There was no statistically significant difference between groups with respect to either cross-sectional IOP values or differences between these values (p>0.05). In Groups B and C, IOP decrease after antiglaucoma drops was statistically significant (p<0.05). Highest post-injection IOP was 26 mmHg in two patients.
Conclusion: Prophylactic use of anti-glaucoma drops (timolol or combination forms) was found to be unnecessary before intravitreal injection of 0.1 ml (2.5 mg) bevacizumab for macular edema or neovascularisation not related to senile macular degeneration since postinjection intraocular pressure increases were statistically insignificant among treatment and control groups.
Keywords : Antiglaucoma medication, intraocular pressure, intravitreal injection, prophylaxis